{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:42:31Z","timestamp":1784238151469,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Ferring Pharmaceuticals A\/S"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s40261-017-0547-7","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T06:00:56Z","timestamp":1498629656000},"page":"873-879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT\/QTc Trial in Healthy Men"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7647-0381","authenticated-orcid":false,"given":"H\u00e5kan","family":"Olsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niclas","family":"Petri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Erichsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Malmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Grundemar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,28]]},"reference":[{"key":"547_CR1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1021\/jm0003900","volume":"44","author":"G Jiang","year":"2001","unstructured":"Jiang G, Stalewski J, Galyean R, et al. GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. J Med Chem. 2001;44:453\u201367.","journal-title":"J Med Chem"},{"key":"547_CR2","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","volume":"102","author":"L Klotz","year":"2008","unstructured":"Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531\u20138.","journal-title":"BJU Int"},{"key":"547_CR3","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.juro.2008.07.033","volume":"180","author":"M Gittelman","year":"2008","unstructured":"Gittelman M, Pommerville PJ, Persson BE, Degarelix Study Group, et al. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol. 2008;180:1986\u201392.","journal-title":"J Urol"},{"key":"547_CR4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.eururo.2008.04.065","volume":"54","author":"H Poppel Van","year":"2008","unstructured":"Van Poppel H, Tombal B, de la Rosette JJ, et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker: results from a 1-year, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol. 2008;54:805\u201313.","journal-title":"Eur Urol"},{"key":"547_CR5","unstructured":"ICH (2005) Guidance for Industry. E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Report No. ICH E14. \n                        https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM073153.pdf\n                        \n                    . Accessed 26 Jun 2017."},{"key":"547_CR6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/13685538.2010.541538","volume":"14","author":"EJ Chahla","year":"2011","unstructured":"Chahla EJ, Hayek ME, Morley JE. Testosterone replacement therapy and cardiovascular risk factors modification. Aging Male. 2011;14:83\u201390.","journal-title":"Aging Male"},{"key":"547_CR7","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/hrt.2010.217414","volume":"97","author":"KS Channer","year":"2011","unstructured":"Channer KS. Endogenous testosterone levels and cardiovascular disease in healthy men. Heart. 2011;97:867\u20139.","journal-title":"Heart"},{"issue":"2 Suppl","key":"547_CR8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1569-9056(04)90218-7","volume":"3","author":"M Garnick","year":"2004","unstructured":"Garnick M, Pratt C, Campion M, et al. Increase in the electrocardiographic QTc interval in men with prostate cancer undergoing androgen deprivation therapy: results of three randomized controlled studies. Eur Urol. 2004;3(2 Suppl):57.","journal-title":"Eur Urol"},{"key":"547_CR9","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1111\/j.1365-2605.2009.00985.x","volume":"33","author":"F Pecori Giraldi","year":"2010","unstructured":"Pecori Giraldi F, Toja PM, Filippini B, et al. Increased prevalence of prolonged QT interval in males with primary or secondary hypogonadism: a pilot study. Int J Androl. 2010;33:e132\u20138.","journal-title":"Int J Androl"},{"key":"547_CR10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1046\/j.1542-474X.2003.08404.x","volume":"8","author":"A Kirilmaz","year":"2003","unstructured":"Kirilmaz A, Bolu E, Kilicaslan F, et al. Comparison of electrocardiographic repolarization patterns between hypogonad males and normal subjects. Ann Noninvas Electrocardiol. 2003;8:284\u20138.","journal-title":"Ann Noninvas Electrocardiol"},{"key":"547_CR11","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.amjcard.2008.11.041","volume":"103","author":"B Charbit","year":"2009","unstructured":"Charbit B, Christin-Ma\u00eetre S, D\u00e9molis JL, et al. Effects of testosterone on ventricular repolarization in hypogonadic men. Am J Cardiol. 2009;103:887\u201390.","journal-title":"Am J Cardiol"},{"key":"547_CR12","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1067\/mhj.2000.109918","volume":"140","author":"H Bidoggia","year":"2000","unstructured":"Bidoggia H, Maciel JP, Capalozza N, et al. Sex differences on the electrocardiographic pattern of cardiac repolarization: possible role of testosterone. Am Heart J. 2000;140:678\u201383.","journal-title":"Am Heart J"},{"key":"547_CR13","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1021\/tx800035b","volume":"21","author":"JS Mitcheson","year":"2008","unstructured":"Mitcheson JS. hERG potassium channels and the structural basis of drug-induced arrhythmias. Chem Res Toxicol. 2008;21:1005\u201310.","journal-title":"Chem Res Toxicol"},{"key":"547_CR14","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1067\/mcp.2000.111482","volume":"68","author":"JL Demolis","year":"2000","unstructured":"Demolis JL, Kubitza D, Tenneze L, et al. Effect of a single oral dose of moxifloxacin (400\u00a0mg and 800\u00a0mg) on ventricular repolarisation in healthy subjects. Clin Pharmacol Ther. 2000;68:658\u201366.","journal-title":"Clin Pharmacol Ther"},{"key":"547_CR15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/157488612802715735","volume":"7","author":"W Haverkamp","year":"2012","unstructured":"Haverkamp W, Kruesmann F, Fritsch A, et al. Update on the cardiac safety of moxifloxacin. Curr Drug Saf. 2012;7:149\u201363.","journal-title":"Curr Drug Saf"},{"key":"547_CR16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1920.tb18266.x","volume":"53","author":"LS Fridericia","year":"1920","unstructured":"Fridericia LS. Duration of systole in electrocardiogram. Acta Med Scand. 1920;53:469.","journal-title":"Acta Med Scand"},{"key":"547_CR17","doi-asserted-by":"crossref","first-page":"17B","DOI":"10.1016\/0002-9149(93)90035-B","volume":"72","author":"C Funck-Brentano","year":"1993","unstructured":"Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol. 1993;72:17B\u201322B.","journal-title":"Am J Cardiol"},{"key":"547_CR18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/10543400802020938","volume":"18","author":"J Zhang","year":"2008","unstructured":"Zhang J, Machado SG. Statistical issues including design and samples size calculation in thorough QT\/QTc studies. J Biopharm Stat. 2008;18:451\u201367.","journal-title":"J Biopharm Stat"},{"key":"547_CR19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.60","volume":"97","author":"B Darpo","year":"2015","unstructured":"Darpo B, Benson C, Dota C, et al. Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin Pharmacol Ther. 2015;97:326\u201335.","journal-title":"Clin Pharmacol Ther"},{"key":"547_CR20","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(08)61307-0","volume":"372","author":"H Morita","year":"2008","unstructured":"Morita H, Wu J, Zipes DP. The QT syndromes: long and short. Lancet. 2008;372:750\u201363.","journal-title":"Lancet"},{"key":"547_CR21","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.juro.2010.08.012","volume":"184","author":"MR Smith","year":"2010","unstructured":"Smith MR, Klotz L, Persson B-E, et al. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol. 2010;184:2313\u20139.","journal-title":"J Urol"},{"key":"547_CR22","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1023\/B:PHAM.0000022403.60314.51","volume":"21","author":"CW Torn\u00f8e","year":"2004","unstructured":"Torn\u00f8e CW, Agers\u00f8 H, Nielsen HA, et al. Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degarelix. Pharm Res. 2004;21:574\u201384.","journal-title":"Pharm Res"},{"key":"547_CR23","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.2165\/10484080-000000000-00000","volume":"69","author":"JE Frampton","year":"2009","unstructured":"Frampton JE, Lyseng-Williamson KA. Degarelix. Drugs. 2009;69:1967\u201376.","journal-title":"Drugs"},{"key":"547_CR24","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.clinthera.2009.11.009","volume":"31","author":"M Steinberg","year":"2009","unstructured":"Steinberg M. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin Ther. 2009;31:2312\u201331.","journal-title":"Clin Ther"},{"key":"547_CR25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1756287211414457","volume":"3","author":"L Boccon-Gibod","year":"2011","unstructured":"Boccon-Gibod L, van der Meulen E, Persson BE. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol. 2011;3:127\u201340.","journal-title":"Ther Adv Urol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-017-0547-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0547-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0547-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T02:05:02Z","timestamp":1503367502000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-017-0547-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,28]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["547"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0547-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,28]]}}}